Health topic
Polycystic ovary syndrome (PCOS)
What is this condition?
A common endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and metabolic features.
Where peptide medicines or pathways fit
Incretin-based medicines are under investigation for metabolic and reproductive outcomes; none are specifically approved for PCOS itself.
Approved versus investigational
Evidence in women by life stage
Kisspeptin modulates GnRH secretion and has been studied in small mechanistic trials in women with PCOS or hypothalamic amenorrhea. Incretin-based medicines are under investigation for metabolic and reproductive outcomes, but none are FDA-approved specifically for PCOS.
Representation and analysis gaps
Trials are small, selected, and often surrogate-endpoint driven; diverse PCOS phenotypes are underrepresented.
Current guideline context
PCOS guidelines focus on lifestyle, hormonal therapy, and metabolic risk management; peptide therapies remain investigational.
What we do not cover
We do not provide fertility, weight-loss, or medication-switching advice.
Related audits
Sources
Secondary context
- guideline
Repository or society guideline source; verify the current edition and issuing organization.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.